Skip to main content
. 2010 Apr 9;86(4):581–591. doi: 10.1016/j.ajhg.2010.02.020

Table 1.

Pathways with Significant Enrichment in the WTCCC data and Significant or Suggestive Enrichment in the DIAGRAM or non-WTCCC Replication Data

Pathwaya Gene Count Genes with eSNP FDRb Pathway Enrichment p Value
Genes with p < 0.01f eSNP eSNP PT2D
WTCCCc Diagramd Non-WTCCCe WTCCC Diagram Non-WTCCCe
Tight junction 186 39% 0.06 1.20 × 10−3 5.40 × 10−3 9.61 × 10−2 MYH1 rs1989811 4.40 × 10−5 1.60 × 10−4 5.23 × 10−2
MYH2 rs2097657 4.40 × 10−5 4.30 × 10−4 1.12 × 10−1
EXOC4 rs6976491 2.10 × 10−4 6.70 × 10−4 8.39 × 10−2
CLDN23 rs2976929 4.30 × 10−4 6.90 × 10−3 3.64 × 10−1
CSNK2B rs1077394 5.50 × 10−4 2.10 × 10−5 1.85 × 10−3

Adherens junction 110 45% 0.18 7.40 × 10−3 2.40 × 10−2 8.08 × 10−2 CSNK2B rs1077394 5.50 × 10−4 2.10 × 10−5 1.85 × 10−3

Calcium signaling pathway 239 39% 0.19 9.60 × 10−3 1.60 × 10−2 3.20 × 10−1 PDE1A rs6711862 2.30 × 10−2 1.70 × 10−3 1.18 × 10−2
GRIN2C rs6501741 3.00 × 10−2 7.10 × 10−3 4.73 × 10−2
ITPR1 rs4684443 1.70 × 10−2 8.00 × 10−3 7.95 × 10−2
AGTR1 rs16861027 3.30 × 10−2 8.30 × 10−3 5.22 × 10−2

Hematopoietic cell lineage 120 33% 0.19 1.70 × 10−2 3.60 × 10−2 3.66 × 10−1 CR1 rs1323720 6.30 × 10−3 6.30 × 10−3 1.13 × 10−1
HLA-DQA1/ HLA-DRB1/ HSPA1B rs1077394 5.50 × 10−4 2.10 × 10−5 1.85 × 10−3
HLA-G rs2256902 8.10 × 10−4 1.10 × 10−3 6.80 × 10−2

Complement and coagulation cascades 108 46% 0.19 1.80 × 10−2 5.30 × 10−2 1.65 × 10−2 CR1 rs1323720 6.30 × 10−3 6.30 × 10−3 1.13 × 10−1
C4A/B rs1077394 5.50 × 10−4 2.10 × 10−5 1.85 × 10−3
C5 rs10818503 4.50 × 10−3 8.80 × 10−3 1.79 × 10−1

PPAR signaling pathway 92 43% 0.2 2.90 × 10−2 2.70 × 10−2 6.46 × 10−1 PPARD rs9368849 7.60 × 10−4 1.70 × 10−3 1.02 × 10−1
SCD rs11190462 9.20 × 10−2 6.10 × 10−3 1.45 × 10−2

Ether lipid metabolism 45 51% 0.2 3.10 × 10−2 2.40 × 10−1 8.03 × 10−2 AGPAT6 rs919035 1.40 × 10−1 3.20 × 10−3 3.75 × 10−3

TGF-β signaling pathway 134 45% 0.2 3.50 × 10−2 2.10 × 10−2 5.44 × 10−2 RBL2 rs4784312 2.30 × 10−4 8.80 × 10−4 1.00 × 10−1
INHBB rs11677557 5.60 × 10−1 3.50 × 10−3 3.44 × 10−4
SMURF2 rs17401012 1.50 × 10−1 9.20 × 10−3 1.42 × 10−2

Antigen processing and presentation 119 41% 0.46 3.90 × 10−2 3.34 × 10−4 2.12 × 10−3 HLA-DQA1/ HLA-DRB1/ HSPA1B rs1077394 5.50 × 10−4 2.10 × 10−5 1.85 × 10−3
HLA-B/ HSPA1L rs2260000 1.80 × 10−3 7.20 × 10−4 2.98 × 10−2
HLA-C rs2596503 3.20 × 10−3 2.40 × 10−3 6.68 × 10−2
HLA-E rs2523589 1.90 × 10−3 1.40 × 10−4 5.48 × 10−3
HLA-G rs2256902 8.10 × 10−4 1.10 × 10−3 6.80 × 10−2
HLA-DMB rs3134954 3.20 × 10−1 5.70 × 10−3 2.43 × 10−3

Pathway gene sizes, p values, FDRs, validation p values, and genes with eSNPs having PT2D ≤ 0.01 in DIAGRAM are presented for the nine pathways with significant (p ≤ 0.05) enrichment in the WTCCC data and significant or suggestive (p ≤ 0.10) enrichment in the DIAGRAM or non-WTCCC data.

a

Pathways are from the Kyoto Encyclopedia of Genes and Genomes (KEGG).

b

FDR is based on 10,000 permutations and 110 pathways tested in total, using the WTCCC T2D GWAS samples.

c

p values are based on 10,000 permutations, using the WTCCC T2D GWAS samples.

d

DIAGRAM Validation p values are based on Komogorov one sided statistic test compared to a uniform distribution, using DIAGRAM T2D GWAS results.

e

Non-WTCCC Validation p values are based on Komogorov one sided statistic test compared to a uniform distribution, using meta-analysis p values derived based DIAGRAM samples excluding WTCCC detection samples.

f

Only pathway genes whose representative eSNPs reached DIAGRAM PT2D ≤ 0.01 are listed here, although there are many more eSNPs associated with each pathway. All representative eSNPs of each pathway are listed in Table S2.